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Bcr-Abl plays a central role in the development of chromosome positive leukaemia. Chronic Myeloid leukaemia
occurs due to increase proliferation and resistance to apoptosis by Bcr-Abl positive cells. Imatinib (STI571) is the first
drug in the family of Bcr-Abl tyrosine kinase inhibitors while Nilotinib (AMN107) and Dasatinib (BMS-345825) are
second generation drugs that are intended to have less resistance and intolerance than imatinib. Ponatinib
(AP24534) an orally active Bcr-Abl Tyrosine Kinase Inhibitor and Bafetinib (INNO-406) have efficacy against various
point mutations in the Bcr-Abl kinase. 1, 3, 4 thiadiazole derivatives has also displayed moderate inhibitory action
on both Abl and Src kinase family. However there are varieties of Bcr-Abl inhibitors but Nilotinib is still the frontline
tyrosine kinase inhibitors.Letter to editor
The Bcr-Abl chimeric protein is thought to play a
central role in the pathogenesis of Philadelphia (Ph)
chromosome-positive leukaemia, notably Chronic Mye-
loid Leukaemia (CML) [1]. This abnormality was discov-
ered by Janet Rowley in 1972 and it is due to the
reciprocal translocation between chromosome 9 and 22.
Three fusion proteins can be formed as a result of
breakpoint in Bcr, all of which exhibit deregulated PTK
activity [2-4]. Basic mechanisms that have been attrib-
uted to Bcr-Abl positive cells, particularly in CML, are
increased proliferation, increased resistance to apoptosis
[5-7], and an alteration of their adhesion properties
[8,9]. Mutational analysis show that the Tyrosine Kinase
activity of the protein is an absolute requirement for malig-
nant transformation, and that it cannot be complemented
by any downstream effectors [10,11]. For these reasons, an
inhibitor of the Bcr-Abl tyrosine kinase should be an effect-
ive and selective treatment for CML.
Selective therapies are aimed for the treatment of
CML because its target is well defined in contrast to
other cancers of body [12]. Hundreds of protein kinases
are known in human genome and a drug was required
that targeted a single ATP binding site of protein kinase
[13]. By blocking the binding of ATP, phosphorylation is* Correspondence: ribakumah@hotmail.com
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reproduction in any medium, provided the orprevented and Bcr- Abl expressing cells either have a
growth disadvantage or they undergo apoptosis [7].
Imatinib (STI571) is the first drug of Bcr-Abl tyrosine
kinase inhibitors that prevents ATP from binding by it-
self binding to Abl domain via six hydrogen bond inter-
actions [14]. Hydrogen bonds involve the pyridine-N
and backbone-NH of Met-318, the aminopyrimidine and
side chain hydroxyl of Thr-315, the amide-NH and side
chain carboxylate of Glu-285, the carbonyl and backbone-
NH of Asp-381, the protonated methylpiperazine with the
backbone-carbonyl atoms of Ile-360 and His-361. Add-
itionally, a number of van der Waals interactions contrib-
ute to binding [13-15]. Resistance faced by imaitinab can
be subdivided into BCR independent and dependant
mechanisms [16]. Dependant mechanism depend upon
the duplication of BCR-ABL tyrosine kinase gene in DNA
sequence leading to higher expression of pathogens [12].
Point mutation in the kinase domain of Bcr-Abl leading to
disrupt in the binding site of imatinib on the tyrosine
kinase, resulting in the loss of sensitivity of drug [16]. The
T315I is a unique mutation because of its resistance to all
approved Bcr-Abl inhibitors, prior to ponatinib [17]. It
may be due to the displacement of cytosine to thiamine
(C->T) base pair at 944 of the Abl gene. It cause the
elimination of critical O2 molecule needed for hydrogen
bonding between imatinab and Bcr-Abl kinases [12].
Most common mutation has been occurred in ATP
binding and activation loop. It cause the derangement
of loops as a result of which kinase domain cannot
assume inactive conformation required for imatinibl Ltd. This is an Open Access article distributed under the terms of the Creative
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due to over expression of P-glycoprotein efflux pump,
activation of Src family kinase or may be because of low
expression, activity or polymorphism of OCT1 [12,18].
Solution for combating resistance is to increase the dose
of imitinab, administration of multiple Abl kinase inhib-
itors and usage of two drugs simultaneously who have
different pathways [16,19]. Nilotinib (AMN107) and
Dasatinib (BMS-345825) are second generation drugs
that are intended to have less resistance and intolerance
than Imatinib [12]. Nilotinib is a selective inhibitor and
binds to the inactive conformation of the Abl kinase do-
main, largely through lipophilic interactions and thus
blocks its catalytic activity, being 10–30 fold potent than
Imatinib [19,20]. Nilotinib binds to kinase domain with
the help of H2 bond interaction involving pyridyl-N and
backbone of NH of Met-318, amino NH and side chain of
OH of Thr 315, amido NH, side chain carboxylate of Glu-
286 and amido carbonyl with backbone NH of Asp −381
[21,22]. It is effective against all type of resistances except
T315I mutation. Its failure against T315I is due to the
loss of an H-bond interaction between threonine-O and
aniline-NH on nilotinib and a steric clash between the
isoleucine-methyl group and 2-methylphenyl phenyl
group of nilotinib [19-21]. Dasatinib is multi targeted
inhibitor of wild type Bcr-Abl and Src family kinases
having additional inhibitory activity against downstream
kinases [23]. Contrary to most Tyrosine Kinase Inhibi-
tors, Dasatinib bind to active conformation of Abl kin-
ase [15]. First and second generations inhibitors have
provided promising results but new mutations are con-
tinuously being encountered that requires discovery of
more drugs.
Bosutinib is based on a quinolone scaffold and is re-
lated to AstraZeneca quinazoline template and it also
had the ability of inhibiting mutation of T3151 [20].
Ponatinib (AP24534) an orally active Bcr-Abl Tyrosine
Kinase Inhibitor effective against the T315I mutation
had been approved for a phase II clinical trial [24].
Bafetinib (INNO-406) with efficacy against various point
mutations in the Bcr-Abl kinase, with fewer adverse
effects and with narrower kinase spectra, is also in phase
II clinical trials [25]. Befitinib and Imatinib has structural
and binding similarities, the notable difference being
hydrophobic interaction between the trifluoromethyl
group and the hydrophobic pocket created by Ile-293,
Leu-298, Leu-354, and Val-379 [26]. 1, 3, 4 thiadiazole
derivatives has also displayed moderate inhibitory action
on both Abl and Src kinases with similar binding prop-
erties as dasatinib, and are still in trials to prove a novel
way to inhibit Tyrosine Kinases [27].
Although there are more potent Bcr-Abl Tyrosine Kin-
ase Inhibitors are available, but Imatinib still remains the
frontline Tyrosine Kinase Inhibitors. Nilotinib, Dasatinib,Bosutinib and Ponatinib are approved for the treatment
of Imatinib resistant or intolerant CML. The availability
of highly potent tyrosine kinase inhibitors, such as
nilotinib, has broadened the treatment armamentarium
in CML. Nilotinib appears to overcome imatinib resist-
ance in patients with chronic, accelerated, and blastic
phase CML, producing sustained cytogenetic and haem-
atological responses [28]. The first line data for these
drugs are encouraging and suggest that some or all of
them may replace Imatinib as a frontline standard Bcr-
Abl tyrosine kinase inhibitor in the near future.
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